Senseonics Holdings, Inc. Reports Second Quarter Financial Results
Senseonics Holdings (NYSE American: SENS) reported Q2 2025 financial results, achieving $6.6 million in revenue, up 37% year-over-year, driven by a 79% increase in U.S. new patient starts. The company raised $77.8 million in total gross proceeds, including $57.5 million from a public offering and $20.3 million from Abbott.
Q2 net loss improved to $14.5 million ($0.02 per share) from $20.3 million in Q2 2024. The company expanded its DTC advertising campaign, completed provider transition to Eon Care, and entered a commercial agreement to integrate Sequel Med Tech's twiist™ AID system with Eversense 365.
For full-year 2025, Senseonics maintains guidance of $34-38 million in global net revenue, expecting to double its global patient base with gross margins between 32.5% and 37.5%.
Senseonics Holdings (NYSE American: SENS) ha comunicato i risultati finanziari del secondo trimestre 2025, registrando 6,6 milioni di dollari di ricavi, in crescita del 37% rispetto all'anno precedente, grazie a un aumento del 79% dei nuovi pazienti negli Stati Uniti. L'azienda ha raccolto 77,8 milioni di dollari di proventi lordi totali, di cui 57,5 milioni da un'offerta pubblica e 20,3 milioni da Abbott.
La perdita netta del secondo trimestre si è ridotta a 14,5 milioni di dollari (0,02 dollari per azione) rispetto ai 20,3 milioni del secondo trimestre 2024. La società ha ampliato la campagna pubblicitaria diretta al consumatore, completato la transizione dei fornitori a Eon Care e stipulato un accordo commerciale per integrare il sistema twiist™ AID di Sequel Med Tech con Eversense 365.
Per l'intero 2025, Senseonics conferma la previsione di 34-38 milioni di dollari di ricavi netti globali, prevedendo di raddoppiare la base globale di pazienti con margini lordi compresi tra il 32,5% e il 37,5%.
Senseonics Holdings (NYSE American: SENS) reportó los resultados financieros del segundo trimestre de 2025, alcanzando 6,6 millones de dólares en ingresos, un aumento del 37% interanual, impulsado por un incremento del 79% en nuevos pacientes en EE. UU. La compañía recaudó 77,8 millones de dólares en ingresos brutos totales, incluyendo 57,5 millones de una oferta pública y 20,3 millones de Abbott.
La pérdida neta del segundo trimestre mejoró a 14,5 millones de dólares (0,02 dólares por acción) desde 20,3 millones en el segundo trimestre de 2024. La empresa amplió su campaña publicitaria directa al consumidor, completó la transición de proveedores a Eon Care y firmó un acuerdo comercial para integrar el sistema twiist™ AID de Sequel Med Tech con Eversense 365.
Para todo el año 2025, Senseonics mantiene la guía de 34-38 millones de dólares en ingresos netos globales, esperando duplicar su base global de pacientes con márgenes brutos entre el 32,5% y el 37,5%.
Senseonics Holdings (NYSE American: SENS)는 2025년 2분기 재무 실적을 발표하며, 660만 달러의 매출을 기록하여 전년 대비 37% 증가했으며, 미국 내 신규 환자 시작이 79% 증가한 것이 주된 원동력입니다. 회사는 공모를 통해 5750만 달러, Abbott로부터 2030만 달러를 포함해 총 7780만 달러의 총 수익을 조달했습니다.
2분기 순손실은 2024년 2분기의 2030만 달러에서 개선되어 1450만 달러(주당 0.02달러)로 감소했습니다. 회사는 직접 소비자 대상 광고 캠페인을 확대하고, 공급자 전환을 Eon Care로 완료했으며, Sequel Med Tech의 twiist™ AID 시스템을 Eversense 365와 통합하는 상업적 계약을 체결했습니다.
2025년 전체에 대해 Senseonics는 전 세계 순매출 3400만~3800만 달러 가이던스를 유지하며, 글로벌 환자 기반을 두 배로 늘리고 총이익률은 32.5%에서 37.5% 사이가 될 것으로 예상합니다.
Senseonics Holdings (NYSE American : SENS) a publié ses résultats financiers du deuxième trimestre 2025, atteignant 6,6 millions de dollars de revenus, en hausse de 37 % d'une année sur l'autre, grâce à une augmentation de 79 % des nouveaux patients aux États-Unis. La société a levé 77,8 millions de dollars de produits bruts totaux, dont 57,5 millions provenant d'une offre publique et 20,3 millions d'Abbott.
La perte nette du deuxième trimestre s'est améliorée pour atteindre 14,5 millions de dollars (0,02 dollar par action) contre 20,3 millions au deuxième trimestre 2024. L'entreprise a élargi sa campagne publicitaire directe aux consommateurs, achevé la transition des prestataires vers Eon Care et conclu un accord commercial pour intégrer le système twiist™ AID de Sequel Med Tech avec Eversense 365.
Pour l'année complète 2025, Senseonics maintient ses prévisions de 34-38 millions de dollars de revenus nets mondiaux, s'attendant à doubler sa base de patients mondiale avec des marges brutes comprises entre 32,5 % et 37,5 %.
Senseonics Holdings (NYSE American: SENS) meldete die Finanzergebnisse für das zweite Quartal 2025 und erzielte 6,6 Millionen US-Dollar Umsatz, ein Wachstum von 37 % im Jahresvergleich, angetrieben durch einen Anstieg der neuen Patientenstarts in den USA um 79 %. Das Unternehmen erzielte insgesamt 77,8 Millionen US-Dollar Bruttoerlöse, darunter 57,5 Millionen aus einem öffentlichen Angebot und 20,3 Millionen von Abbott.
Der Nettoverlust im zweiten Quartal verbesserte sich auf 14,5 Millionen US-Dollar (0,02 US-Dollar pro Aktie) gegenüber 20,3 Millionen im zweiten Quartal 2024. Das Unternehmen erweiterte seine Direktkunden-Werbekampagne, schloss den Anbieterwechsel zu Eon Care ab und ging eine kommerzielle Vereinbarung zur Integration des twiist™ AID-Systems von Sequel Med Tech mit Eversense 365 ein.
Für das Gesamtjahr 2025 hält Senseonics die Prognose von 34-38 Millionen US-Dollar globalem Nettoumsatz aufrecht und erwartet eine Verdopplung der globalen Patientenbasis bei Bruttomargen zwischen 32,5 % und 37,5 %.
- Revenue growth of 37% year-over-year to $6.6 million
- 79% increase in U.S. new patient starts compared to prior year
- Successful fundraising of $77.8 million through public offering and Abbott investment
- Net loss decreased by $5.8 million year-over-year
- R&D expenses decreased by $3.1 million due to completion of 365-day product trials
- CMS updated Medicare Physician Fee Schedule to cover full year of Eversense 365 usage
- Operating cash burn expected at $60 million for 2025
- International revenue declined to $1.7 million from $1.9 million year-over-year
- SG&A expenses increased by $0.7 million year-over-year
- Continued net loss of $14.5 million despite improvements
Insights
Senseonics shows 37% revenue growth and 79% U.S. patient growth, with strategic advances suggesting improved commercial traction for its implantable CGM technology.
Senseonics delivered
Gross profit jumped significantly to
Operating expenses show a company transitioning from R&D-heavy to commercialization phases. R&D expenses decreased by
Several strategic developments strengthen Senseonics' market position: 1) Enhanced direct-to-consumer advertising yielding
The company's
Generated Q2 revenue of
Achieved a
GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2025.
Recent Highlights & Accomplishments:
- Generated revenue of
$6.6 million in the second quarter of 2025, an increase of37% versus the second quarter of 2024, driven by79% new patient growth in the U.S. over prior year - Expanded direct-to-consumer (DTC) advertising campaign to drive further awareness and adoption of Eversense in the U.S., with the first month of enhanced campaign generating a
50% increase in leads over prior three-month average - Completed transition of providers to Eon Care from the Nurse Practitioner Group (NPG), now with 38 providers to support patient access to insertions
- CMS updated the Medicare Physician Fee Schedule, providing reimbursement for a full year of usage with Eversense 365 as a medical benefit
- Entered into a commercial development agreement to integrate Sequel Med Tech’s twiist™ automated insulin delivery (AID) system with Eversense 365, with launch expected in Q4
- Raised
$77.8 million in total gross proceeds, including$57.5 million in a public offering and$20.3 million from Abbott in a concurrent private placement, to fund the ongoing launch of Eversense 365 and continued development of pipeline products
“During the quarter we continued to drive a strong U.S. Eversense 365 launch focused on new patients, initiating enhanced DTC advertising in June to broaden actionable leads and enable acceleration in patients and revenue growth in the second half of the year,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “We advanced several other important strategic initiatives which drive uptake and advance our technology to position us for increased shareholder value while progressing the development of Gemini and Freedom.”
Second Quarter 2025 Results:
Total revenue for the second quarter of 2025 was
Second quarter 2025 gross profit of
Second quarter 2025 research and development expenses decreased by
Second quarter 2025 selling, general and administrative expenses increased by
Net loss was
Full Year 2025 Financial Outlook
Senseonics continues to expect full-year 2025 global net revenue to be approximately
Conference Call and Webcast Information:
Company management will host a conference call at 4:30 pm (Eastern Time) today, August 6, 2025, to discuss these financial results and recent business developments. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at this link. Individuals interested in participating in the call via telephone may access the call by dialing +1-800-225-9448 (+1-203-518-9708 for those outside the U.S. or Canada) and referencing Conference ID SENSQ2. A replay of the call can be accessed on Senseonics’ website http://www.senseonics.com under “Investor Relations.”
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives. We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2024 were JPY 353.9 billion with global distribution of products and services in more than 125 countries. www.phchd.com
©2025 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue, gross margin, cash flow and global installed customer base projections, and global installed customer base and reorder assumptions, under the heading “Full Year 2025 Financial Outlook,” statements regarding plans, timing and success of the commercial launch of the 365-day system and the adoption of, access to, or growth of use of Eversense, statements regarding future demand for Eversense, statements regarding development programs and next generation systems, statements regarding the collaboration with Sequel and the anticipated timing for commercial availability of an integrated twiistTM AID system with Eversense 365, the future regulatory approval and the potential to commercially launch Eversense 365 outside the U.S., and other statements containing the words "believe," “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the reliance on and execution of Ascensia Diabetes Care, the Company’s commercialization partner for Eversense, uncertainties with respect to any additional commercial support that will be required for successful commercialization of Eversense, and other commercial initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration and roll-out of new technology and solutions, uncertainties inherent in finalizing integration and commercial terms and coordination with health systems and other new collaboration partners and third parties, uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of the Eversense product and Senseonics’ and its partners’ activities, uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024, the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and future reports filed with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
Senseonics Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) | ||||||||
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 31,518 | $ | 74,597 | ||||
| Restricted cash | 315 | 315 | ||||||
| Short term investments, net | 94,894 | — | ||||||
| Accounts receivable, net | 2,853 | 1,365 | ||||||
| Accounts receivable, net - related parties | 2,304 | 4,921 | ||||||
| Inventory, net | 4,714 | 4,421 | ||||||
| Prepaid expenses and other current assets | 4,990 | 5,819 | ||||||
| Total current assets | 141,588 | 91,438 | ||||||
| Deposits and other assets | 4,729 | 4,926 | ||||||
| Property, equipment and intangible assets, net | 3,957 | 4,074 | ||||||
| Total assets | $ | 150,274 | $ | 100,438 | ||||
| Liabilities and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,269 | $ | 3,205 | ||||
| Accrued expenses and other current liabilities | 9,883 | 13,636 | ||||||
| Accrued expenses and other current liabilities, related parties | 2,624 | 1,870 | ||||||
| Notes payable, current portion, net | — | 20,138 | ||||||
| Total current liabilities | 14,776 | 38,849 | ||||||
| Long-term debt and notes payables, net | 35,230 | 34,703 | ||||||
| Non-current operating lease liabilities | 5,548 | 5,785 | ||||||
| Total liabilities | 55,554 | 79,337 | ||||||
| Preferred stock and additional paid-in-capital, subject to possible redemption: | — | 37,656 | ||||||
| Total temporary equity | — | 37,656 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity (deficit): | ||||||||
| Common stock, | 815 | 595 | ||||||
| Additional paid-in capital | 1,070,516 | 930,724 | ||||||
| Accumulated other comprehensive loss | 23 | — | ||||||
| Accumulated deficit | (976,634 | ) | (947,874 | ) | ||||
| Total stockholders’ equity (deficit) | 94,720 | (16,555 | ) | |||||
| Total liabilities, temporary equity and stockholders’ equity (deficit) | $ | 150,274 | $ | 100,438 | ||||
| Senseonics Holdings, Inc. Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue, net | $ | 3,223 | $ | 778 | $ | 5,033 | $ | 1,367 | ||||||||
| Revenue, net - related parties | 3,426 | 4,087 | 7,873 | 8,545 | ||||||||||||
| Total revenue | 6,649 | 4,865 | 12,906 | 9,912 | ||||||||||||
| Cost of sales | 3,528 | 4,567 | 8,280 | 9,279 | ||||||||||||
| Gross profit | 3,121 | 298 | 4,626 | 633 | ||||||||||||
| Expenses: | ||||||||||||||||
| Research and development expenses | 7,715 | 10,800 | 15,014 | 21,238 | ||||||||||||
| Selling, general and administrative expenses | 9,729 | 8,991 | 17,423 | 17,119 | ||||||||||||
| Operating loss | (14,323 | ) | (19,493 | ) | (27,811 | ) | (37,724 | ) | ||||||||
| Other (expense) income, net: | ||||||||||||||||
| Interest income | 973 | 1,190 | 1,648 | 2,574 | ||||||||||||
| Interest expense | (1,145 | ) | (2,085 | ) | (2,574 | ) | (4,133 | ) | ||||||||
| Gain on change in fair value of derivatives | — | 102 | — | 102 | ||||||||||||
| Other (expense) income | (6 | ) | (1 | ) | (23 | ) | 17 | |||||||||
| Total other (expense) income, net | (178 | ) | (794 | ) | (949 | ) | (1,440 | ) | ||||||||
| Net Loss | (14,501 | ) | (20,287 | ) | (28,760 | ) | (39,164 | ) | ||||||||
| Other comprehensive loss | ||||||||||||||||
| Unrealized gain (loss) on marketable securities | 26 | (5 | ) | 23 | 4 | |||||||||||
| Other comprehensive gain (loss) | 26 | (5 | ) | 23 | 4 | |||||||||||
| Total comprehensive loss | $ | (14,475 | ) | $ | (20,292 | ) | $ | (28,737 | ) | $ | (39,160 | ) | ||||
| Basic net loss per common share | $ | (0.02 | ) | $ | (0.03 | ) | $ | (0.04 | ) | $ | (0.06 | ) | ||||
| Basic weighted-average shares outstanding | 813,364,903 | 616,585,664 | 766,382,267 | 615,587,105 | ||||||||||||
| Diluted net loss per common share | $ | (0.02 | ) | $ | (0.03 | ) | $ | (0.04 | ) | $ | (0.06 | ) | ||||
| Diluted weighted-average shares outstanding | 813,364,903 | 616,585,664 | 766,382,267 | 615,587,105 | ||||||||||||
FAQ
What were Senseonics (SENS) Q2 2025 earnings results?
How much funding did Senseonics (SENS) raise in Q2 2025?
What is Senseonics (SENS) revenue guidance for 2025?
How did Senseonics (SENS) U.S. patient growth perform in Q2 2025?
What strategic partnerships did Senseonics (SENS) announce in Q2 2025?
